{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:59:57Z","timestamp":1785146397012,"version":"3.55.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic uses of mesenchymal stromal cells (MSCs) have emerged over the past decade. Yet, their effect on tumor growth remains highly debated, particularly in an immune competent environment. In this study, we wanted to investigate the impact of human umbilical cord\u2013derived MSCs (hUC-MSCs) on tumor growth in humanized mice generated by the human adoptive transfer of PBMCs or the cotransplantation of hematopoietic stem cells and human thymic tissue (human BLT [Hu-BLT]). Our results showed that the growth and immune rejection of engineered human fibroblastic tumors was not altered by the injection of hUC-MSCs in immune-deficient or humanized mice, respectively. This was observed whether tumor cells were injected s.c. or i.v. and independently of the injection route of the hUC-MSCs. Moreover, only in Hu-BLT mice did hUC-MSCs have some effects on the tumor-immune infiltrate, yet without altering tumor growth. These results demonstrate that hUC-MSCs do not promote fibroblastic tumor growth and neither do they prevent tumor infiltration and rejection by immune cells in humanized mice.<\/jats:p>","DOI":"10.4049\/jimmunol.1900807","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:35:13Z","timestamp":1570030513000},"page":"2735-2745","source":"Crossref","is-referenced-by-count":14,"title":["The Tumor-Immune Response Is Not Compromised by Mesenchymal Stromal Cells in Humanized Mice"],"prefix":"10.1093","volume":"203","author":[{"given":"Ga\u00ebl","family":"Moquin-Beaudry","sequence":"first","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine , Montreal, Quebec H3T 1C5 ,","place":["Canada"]},{"name":"D\u00e9partement de Pharmacologie et Physiologie, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec H3T 1J4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Colas","sequence":"additional","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine , Montreal, Quebec H3T 1C5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Li","sequence":"additional","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine , Montreal, Quebec H3T 1C5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-2532","authenticated-orcid":false,"given":"Ren\u00e9e","family":"Bazin","sequence":"additional","affiliation":[{"name":"Direction de l\u2019Innovation, Affaires M\u00e9dicales et Innovation, H\u00e9ma-Qu\u00e9bec , Quebec G1V 5C3 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean V","family":"Guimond","sequence":"additional","affiliation":[{"name":"Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux, Centre-Sud-de-l\u2019\u00cele-de-Montr\u00e9al , Montreal, Quebec H1T 2M4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Haddad","sequence":"additional","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine , Montreal, Quebec H3T 1C5 ,","place":["Canada"]},{"name":"D\u00e9partement de P\u00e9diatrie, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec H3T 1J4 ,","place":["Canada"]},{"name":"D\u00e9partement de Microbiologie, Immunologie et Infectiologie, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec H3T 1J4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Beaus\u00e9jour","sequence":"additional","affiliation":[{"name":"Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine , Montreal, Quebec H3T 1C5 ,","place":["Canada"]},{"name":"D\u00e9partement de Pharmacologie et Physiologie, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec H3T 1J4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"2025030417544120500_r1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","article-title":"Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation","volume":"21","author":"Zhao","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2025030417544120500_r2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"2025030417544120500_r3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/TP.0b013e31821aba18","article-title":"Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. [Published erratum appears in 2011 Transplantation 92: e61.]","volume":"91","author":"Wu","year":"2011","journal-title":"Transplantation"},{"key":"2025030417544120500_r4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4252\/wjsc.v6.i2.163","article-title":"Mesenchymal stem cells help pancreatic islet transplantation to control type 1 diabetes","volume":"6","author":"Figliuzzi","year":"2014","journal-title":"World J. Stem Cells"},{"key":"2025030417544120500_r5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/MOT.0000000000000029","article-title":"Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials","volume":"18","author":"Pileggi","year":"2013","journal-title":"Curr. Opin. Organ Transplant."},{"key":"2025030417544120500_r6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/gut.2010.215152","article-title":"Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study","volume":"59","author":"Duijvestein","year":"2010","journal-title":"Gut"},{"key":"2025030417544120500_r7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ahj.2012.05.026","article-title":"Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF Trial)","volume":"164","author":"Mathiasen","year":"2012","journal-title":"Am. Heart J."},{"key":"2025030417544120500_r8","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417544120500_r9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/TP.0b013e318291a2da","article-title":"Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study","volume":"95","author":"Orozco","year":"2013","journal-title":"Transplantation"},{"key":"2025030417544120500_r10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10238-012-0218-1","article-title":"Therapeutic application of mesenchymal stem cells in bone and joint diseases","volume":"14","author":"Liu","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"2025030417544120500_r11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"2025030417544120500_r12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2025030417544120500_r13","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1634\/stemcells.2007-1028","article-title":"Immune properties of human umbilical cord Wharton\u2019s jelly-derived cells","volume":"26","author":"Weiss","year":"2008","journal-title":"Stem Cells"},{"key":"2025030417544120500_r14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14653240903079401","article-title":"Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions","volume":"11","author":"Girdlestone","year":"2009","journal-title":"Cytotherapy"},{"key":"2025030417544120500_r15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/icb.2010.47","article-title":"Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO","volume":"88","author":"Tipnis","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"2025030417544120500_r16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","article-title":"Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility","volume":"6","author":"Nagamura-Inoue","year":"2014","journal-title":"World J. Stem Cells"},{"key":"2025030417544120500_r17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1089\/scd.2009.0485","article-title":"Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton\u2019s jelly of umbilical cord","volume":"19","author":"Hsieh","year":"2010","journal-title":"Stem Cells Dev."},{"key":"2025030417544120500_r18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1634\/stemcells.2004-0166","article-title":"Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors","volume":"23","author":"Sarugaser","year":"2005","journal-title":"Stem Cells"},{"key":"2025030417544120500_r19","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1634\/stemcells.2006-0709","article-title":"Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow","volume":"25","author":"Baksh","year":"2007","journal-title":"Stem Cells"},{"key":"2025030417544120500_r20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12015-010-9166-x","article-title":"Human Wharton\u2019s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells","volume":"7","author":"Fong","year":"2011","journal-title":"Stem Cell Rev Rep"},{"key":"2025030417544120500_r21","doi-asserted-by":"crossref","first-page":"e0127992","DOI":"10.1371\/journal.pone.0127992","article-title":"Comparative characterization of cells from the various compartments of the human umbilical cord shows that the wharton\u2019s jelly compartment provides the best source of clinically utilizable mesenchymal stem cells","volume":"10","author":"Subramanian","year":"2015","journal-title":"PLoS One"},{"key":"2025030417544120500_r22","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jcb.24057","article-title":"Human umbilical cord Wharton\u2019s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells","volume":"113","author":"Subramanian","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"2025030417544120500_r23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jcb.24661","article-title":"Human Wharton\u2019s jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. [Published erratum appears in 2017 J. Cell Biochem. 118: 3016.]","volume":"115","author":"Fong","year":"2014","journal-title":"J. Cell Biochem."},{"key":"2025030417544120500_r24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","article-title":"Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients","volume":"27","author":"Zhang","year":"2012","journal-title":"J. Gastroenterol Hepatol."},{"key":"2025030417544120500_r25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"2025030417544120500_r26","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1371\/journal.pone.0001451","article-title":"Islet-like clusters derived from mesenchymal stem cells in Wharton\u2019s jelly of the human umbilical cord for transplantation to control type 1 diabetes","volume":"3","author":"Chao","year":"2008","journal-title":"PLoS One"},{"key":"2025030417544120500_r27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/14653249.2011.651532","article-title":"Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q","volume":"14","author":"Qiu","year":"2012","journal-title":"Cytotherapy"},{"key":"2025030417544120500_r28","doi-asserted-by":"crossref","first-page":"e9016","DOI":"10.1371\/journal.pone.0009016","article-title":"Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially","volume":"5","author":"Prasanna","year":"2010","journal-title":"PLoS One"},{"key":"2025030417544120500_r29","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.bbmt.2007.08.048","article-title":"Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation","volume":"13","author":"Friedman","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2025030417544120500_r30","first-page":"1230","article-title":"Human umbilical cord mesenchymal stem cells and exosomes: bioactive ways of tissue injury repair","volume":"11","author":"Yin","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"2025030417544120500_r31","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"2025030417544120500_r32","doi-asserted-by":"crossref","first-page":"30193","DOI":"10.18632\/oncotarget.8623","article-title":"Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming","volume":"7","author":"Selleri","year":"2016","journal-title":"Oncotarget"},{"key":"2025030417544120500_r33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0065-230X(10)07003-X","article-title":"Regulatory T cells in cancer","volume":"107","author":"Mougiakakos","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"2025030417544120500_r34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/scd.2013.0363","article-title":"Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells","volume":"23","author":"Castro-Manrreza","year":"2014","journal-title":"Stem Cells Dev."},{"key":"2025030417544120500_r35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/scd.2009.0345","article-title":"Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders","volume":"19","author":"Zhao","year":"2010","journal-title":"Stem Cells Dev."},{"key":"2025030417544120500_r36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/stem.269","article-title":"Mesenchymal stromal cells: current understanding and clinical status","volume":"28","author":"Salem","year":"2010","journal-title":"Stem Cells"},{"key":"2025030417544120500_r37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2141.2005.05409.x","article-title":"Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells","volume":"129","author":"Puissant","year":"2005","journal-title":"Br. J. Haematol."},{"key":"2025030417544120500_r38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cells"},{"key":"2025030417544120500_r39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s13058-014-0410-1","article-title":"Cancer\/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression","volume":"16","author":"Chen","year":"2014","journal-title":"Breast Cancer Res."},{"key":"2025030417544120500_r40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.intimp.2017.03.024","article-title":"IDO1: an important immunotherapy target in cancer treatment. [Published erratum appears in 2017 Int. Immunopharmacol. 49: 231.]","volume":"47","author":"Li","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"2025030417544120500_r41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"2025030417544120500_r42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1477-7819-11-118","article-title":"Nitric oxide and cancer: a review","volume":"11","author":"Choudhari","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"2025030417544120500_r43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tibs.2013.10.001","article-title":"Signaling interplay between transforming growth factor-\u03b2 receptor and PI3K\/AKT pathways in cancer","volume":"38","author":"Zhang","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"2025030417544120500_r44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/cancers9040035","article-title":"Hepatocyte growth factor, a key tumor-promoting Factor in the tumor microenvironment","volume":"9","author":"Owusu","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2025030417544120500_r45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"2025030417544120500_r46","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"2025030417544120500_r47","first-page":"1","volume-title":"Encyclopedia of Cancer.","author":"Haynes","year":"2015"},{"key":"2025030417544120500_r48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.559","article-title":"Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?","volume":"29","author":"Klopp","year":"2011","journal-title":"Stem Cells"},{"key":"2025030417544120500_r49","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1111\/cas.13334","article-title":"Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential","volume":"108","author":"Lee","year":"2017","journal-title":"Cancer Sci."},{"key":"2025030417544120500_r50","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/emboj\/cdg417","article-title":"Reversal of human cellular senescence: roles of the p53 and p16 pathways","volume":"22","author":"Beaus\u00e9jour","year":"2003","journal-title":"EMBO J."},{"key":"2025030417544120500_r51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ydbio.2011.03.004","article-title":"Conditional expression of the TVA receptor allows clonal analysis of descendents from Cre-expressing progenitor cells","volume":"353","author":"Beier","year":"2011","journal-title":"Dev. Biol."},{"key":"2025030417544120500_r52","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","article-title":"Humanized mice for immune system investigation: progress, promise and challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"2025030417544120500_r53","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jcyt.2018.05.010","article-title":"Functional impairment of MSC induced by transient warming events: correlation with loss of adhesion and altered cell size","volume":"20","author":"Chabot","year":"2018","journal-title":"Cytotherapy"},{"key":"2025030417544120500_r54","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jcyt.2017.04.005","article-title":"Transient warming events occurring after freezing impairs umbilical cord-derived mesenchymal stromal cells functionality","volume":"19","author":"Chabot","year":"2017","journal-title":"Cytotherapy"},{"key":"2025030417544120500_r55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"2025030417544120500_r56","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/eji.200939480","article-title":"High diversity of the immune repertoire in humanized NOD.SCID.gamma c-\/- mice","volume":"39","author":"Marodon","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"2025030417544120500_r57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/mi.2012.31","article-title":"IL-2 receptor \u03b3-chain molecule is critical for intestinal T-cell reconstitution in humanized mice","volume":"5","author":"Denton","year":"2012","journal-title":"Mucosal Immunol."},{"key":"2025030417544120500_r58","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2017","journal-title":"FASEB J."},{"key":"2025030417544120500_r59","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.18632\/oncotarget.14026","article-title":"Autologous reconstitution of human cancer and immune system in vivo","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"2025030417544120500_r60","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.4049\/jimmunol.181.6.4406","article-title":"CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors","volume":"181","author":"Tatum","year":"2008","journal-title":"J. Immunol."},{"key":"2025030417544120500_r61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"2025030417544120500_r62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1745-6215-12-62","article-title":"The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments","volume":"12","author":"Connick","year":"2011","journal-title":"Trials"},{"key":"2025030417544120500_r63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.exphem.2007.11.007","article-title":"Mesenchymal cells recruit and regulate T regulatory cells","volume":"36","author":"Di Ianni","year":"2008","journal-title":"Exp. Hematol."},{"key":"2025030417544120500_r64","doi-asserted-by":"crossref","first-page":"394917","DOI":"10.1155\/2015\/394917","article-title":"Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications","volume":"2015","author":"Castro-Manrreza","year":"2015","journal-title":"J. Immunol. Res."},{"key":"2025030417544120500_r65","first-page":"516","article-title":"Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory\/suppressive phenotype","volume":"90","author":"Maccario","year":"2005","journal-title":"Haematologica"},{"key":"2025030417544120500_r66","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.11240","article-title":"Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction","volume":"92","author":"Prevosto","year":"2007","journal-title":"Haematologica"},{"key":"2025030417544120500_r67","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","article-title":"Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor","volume":"180","author":"Carson","year":"1994","journal-title":"J. Exp. Med."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/10\/2735\/61418329\/ji1900807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/10\/2735\/61418329\/ji1900807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:12:02Z","timestamp":1741101122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/203\/10\/2735\/7952218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,11,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1900807","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/699751","asserted-by":"object"}]},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,11]]}}}